A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 3, 2013, Pages 394-399

  Blake, C M ^a   Kharasch, E D ^a   Schwab, M ^b,c   Nagele, P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; METOPROLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED RELEASE FORMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENANTIOMER; GENE DOSAGE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; PHENOTYPE; PRIORITY JOURNAL; STEREOCHEMISTRY; SYSTEMATIC REVIEW; CHEMISTRY; GENETICS; META ANALYSIS; METABOLISM; STEREOISOMERISM;

ADRENERGIC BETA-ANTAGONISTS; CYTOCHROME P-450 CYP2D6; GENE DOSAGE; HUMANS; METOPROLOL; PHENOTYPE; STEREOISOMERISM;

EID: 84883189342     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.96     Document Type: Article

References (30)

1. Lennard, M.S., Silas, J.H., Freestone, S., Ramsay, L.E., Tucker, G.T. & Woods, H.F. Oxidation phenotype-a major determinant of metoprolol metabolism and response. N. Engl. J. Med. 307, 1558-1560 (1982).
2. Gardiner, S.J. & Begg, E.J. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol. Rev. 58, 521-590 (2006).
3. Nagele, P. & Liggett, S.B. Genetic variation, ß-blockers, and perioperative myocardial infarction. Anesthesiology 115, 1316-1327 (2011).
4. Daly, A.K. et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6, 193-201 (1996).
5. McDonagh, E.M., Whirl-Carrillo, M., Garten, Y., Altman, R.B. & Klein, T.E. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark. Med. 5, 795-806 (2011).
6. Zanger, U.M. & Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138, 103-141 (2013).
7. Rau, T. et al. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin. Pharmacol. Ther. 85, 269-272 (2009).
8. Hamelin, B.A. et al. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin. Pharmacol. Ther. 67, 466-477 (2000).
9. Hemeryck, A., Lefebvre, R.A., De Vriendt, C. & Belpaire, F.M. Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin. Pharmacol. Ther. 67, 283-291 (2000).
10. Huang, J., Chuang, S.K., Cheng, C.L. & Lai, M.L. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes. Clin. Pharmacol. Ther. 65, 402-407 (1999).
11. Jin, S.K. et al. Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. J. Clin. Pharm. Ther. 33, 567-573 (2008).
12. Kirchheiner, J. et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 76, 302-312 (2004).
13. Parker, R.B. & Soberman, J.E. Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol. Pharmacotherapy 31, 630-641 (2011).
14. Seeringer, A., Brockmöller, J., Bauer, S. & Kirchheiner, J. Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. Eur. J. Clin. Pharmacol. 64, 883-888 (2008).
15. Sharma, A. et al. Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women. J. Pharmacol. Exp. Ther. 313, 1172-1181 (2005).
16. Sharma, A. et al. Toward optimal treatment in women: the effect of sex on metoprolol-diphenhydramine interaction. J. Clin. Pharmacol. 50, 214-225 (2010).
17. Somer, M., Kallio, J., Pesonen, U., Pyykkö, K., Huupponen, R. & Scheinin, M. Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br. J. Clin. Pharmacol. 49, 549-554 (2000).
18. Wang, Y. et al. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. Br. J. Clin. Pharmacol. 65, 885-892 (2008).
19. Werner, U. et al. Valdecoxib does not interfere with the CYP2D6 substrate metoprolol. Int. J. Clin. Pharmacol. Ther. 44, 397-400 (2006).
20. Werner, U., Werner, D., Rau, T., Fromm, M.F., Hinz, B. & Brune, K. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin. Pharmacol. Ther. 74, 130-137 (2003).
21. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353, 9-13 (1999).
22. DiNicolantonio, J.J., Lavie, C.J., Fares, H., Menezes, A.R. & O'Keefe, J.H. Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol). Am. J. Cardiol. 111, 765-769 (2013).
23. Poole-Wilson, P.A. et al.; Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362, 7-13 (2003).
24. Moher, D., Liberati, A., Tetzlaff, J. & Altman, D.G.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 151, 264-9, W64 (2009).
25. Sachse, C., Brockmöller, J., Bauer, S. & Roots, I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60, 284-295 (1997).
26. Griese, E.U. et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8, 15-26 (1998).
27. Zanger, U.M. et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11, 573-585 (2001).
28. Zhou, S.F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin. Pharmacokinet. 48, 689-723 (2009).
29. Swen, J.J. et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin. Pharmacol. Ther. 89, 662-673 (2011).
30. Fieller, E. The biological standardization of insulin. J R Statist Soc. 7, S1-S46 (1940).